FEATURE
Clinical development success rates for investigational drugs
Michael Hay, David W Thomas, John L Craighead, Celia Economides & Jesse Rosenthal
The most comprehensive survey of clinical success rates across the drug industry to date shows productivity may be even lower than previous estimates.
ince the human genome was sequenced ten years ago, the number of compounds in development has increased 62% and total R&D expenditures have doubled1–3. And yet, the average number of new drugs approved by the US Food and Drug Administration (FDA) per year has declined since the 1990s. In 2012, 39 novel drugs classified as new molecular entities (NMEs) and biologic license applications (BLAs) were approved by the FDA4. Although this represents the highest number of approvals since 1997 and is nearly 50% above the average of 26 approv-als per year over the past decade, 25% fewer NME and BLA drugs were approved on aver-age in the past 10 years compared with the 1990s5. Several possible explanations for the divergence of R&D spending and new product approvals have been offered by professionals in the industry, such as unbalanced regulatory risk-benefit assessments, higher regulatory efficacy hurdles, commercial and financial decisions driving project termination, and the increased complexity and cost of clinical trials6,7.
This article aims to measure clinical devel-opment success rates across the industry with a view to strengthening benchmarking met-rics for drug development. The study is the largest and most recent of its kind, examining success rates of 835 drug developers, includ-ing biotech companies as well as specialty and
Michael Hay and Jesse Rosenthal are at
BioMedTracker, Sagient Research Systems, San Diego, California, USA; David W. Thomas and Celia Economides are at the Biotechnology Industry Organization (BIO), Washington, DC, USA; and John L. Craighead is at Biotech Strategy & Analytics, Rockville, Maryland, USA. e-mail: mhay@sagientresearch.com
© 2014 Nature America, Inc. All rights reserved.
S
large pharmaceutical firms from 2003 to 2011. Success rates for over 7,300 independent drug development paths are analyzed by clinical phase, molecule type, disease area and lead versus nonlead indication status.
Our results pinpoint weaknesses along the capital-intensive pathway to drug approval. Our hope is that they will prove useful in informing policy makers where to focus changes in regulation and strengthen valua-tion models used by industry and the invest-ment community.
Analyzing success
To measure clinical development success rates for investigational drugs, we analyzed phase transitions from January 1, 2003 to December 31, 2011, in the BioMedTracker database. The BioMedTracker data set contained 4,451 drugs with 7,372 independent clinical development paths from 835 companies and included 5,820 phase transitions. The development paths comprised lead (primary) and nonlead (sec-ondary) indications, with roughly 38% desig-nated as nonlead. A more detailed description of the data collection, composition and analy-sis methodology is described in Boxes 1–3 (see also Tables 1 and 2).
Unlike many previous studies that reported clinical development success rates for large pharmaceutical companies, this study pro-vides a benchmark for the broader drug devel-opment industry by including small public and private biotech companies and specialty phar-maceutical firms. The aim is to incorporate data from a wider range of clinical develop-ment organizations, as well as drug modalities and targets. Two landmark publications on the subject, DiMasi et al.6 and Kola et al.8 use 50 and 10 pharmaceutical company pipelines, respectively, to arrive at their conclusions. An important study published by the US Federal Trade Commission Bureau of Economics, Abrantes-Metz et al.9 covered a wide num-ber of drugs over a 14 year period from 1989 to 2002, but did not provide the number or type of companies investigated. Although the impact of company size and experience on R&D productivity has been studied exten-sively10–13, success rates established by DiMasi et al.6, Kola et al.8 and Abrantes-Metz et al.9 remain the primary benchmarks for the drug development industry.
We believe it is of great value to report updated success rates that capture the diver-sity in drug development sponsor types as experience and technology vary widely out-side of traditional, large pharmaceutical cor-porations. Furthermore, the more recent time frame for this study provides insight into the latest industry productivity. A comparison of previously published reports with the current study is summarized in Table 3 and is dis-cussed below.
One key distinction of the study pre-sented here is our ability to evaluate all of a drug’s indications to determine success rates. Danzon et al.12 first considered suc-cess rates at the indication level, recognizing that FDA requires clinical trial evidence to establish efficacy for each approved indi-cation. Although these authors included data from 1988 to 2000, an observation period similar to Kola et al.8 and Abrantes-Metz et al.9, their success rates were sig-nificantly higher and lacked a characteristic decrease in phase 2 probability reported in previous studies as well as here. Danzon et al.12 concluded that higher clinical develop-ment success rates resulted from the analysis of all indications. Even so, evidence presented here strongly suggests that evaluating all indications results in lower probabilities of success across all phases of drug development.
p40 volume 32 NumBeR 1 JANuARY 2014 nature biotechnology
* Michael Hay et al., “Clinical Development Success Rates for Investigational Drugs,” Nature Biotechnology 32, no. 1 (2014): 4051. See more at http...
success rates for investigational drugs 〔 J 〕.( 3 ): 272. 〔7 〕 Wendler A, Wehling M. Clin Pharmacol Ther, 2010 , 87 development: eight case...
Drugs of the Future 2014, 39(4): 309-316 ... is an investigational NNRTI that was previously ...has been chosen for further clinical development. ...
热门文档